MEDIGENE AG

MEDIGENE AG

Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus on T cell receptor-modified T cells in areas of unmet medical needs, which are in clinical development. It also focuses on dendritic cell vaccines and T cell-specific monoclonal antibodies. In addition, the company focuses on developing and marketing RhuDex for hepatology and gastroenterology indication... s. Medigene AG has a strategic partnership with bluebird bio, Inc. for the development of T cell receptors. The company also has research collaboration agreements on novel cancer antigens for immunotherapies with the Université de Montréal; and with Cytovant Sciences Co. Ltd. It has operations in Europe, the United States, Asia, and internationally. The company was founded in 1994 and is headquartered in Munich, Germany.

Medigene Ag_logo

Industry:
Listed Biotechnology Company

Founded:
1994

Address:
Lochhamer Strasse 11, Munich, Germany Zipcode 82152

Country:
United Kingdom

Phone:
49 89 200033 0

Company Size Range:
51 - 200
Current Employees:
38
Total Employees:
145

Market Cap:
95.82M
Total Revenue:
8M
Total Assets:
74.75M
Total Cash:
30.03M

Subsidiaries: Munich Biotech AG · Neurovir Therapeutics · Trianta Immunotherapies GmbH · MediGene, Inc.


Key Executives
Name Title Pay Year Born
Dr. Dolores J. Schendel CEO, Chief Scientific Officer & Member of Exec. Management Board 375,000$ N/A
Mr. Axel Sven Malkomes CFO, Chief Bus. Devel. Officer & Member of Exec. Management Board 408,000$ N/A
Dr. Kai Pinkernell Advisor 409,000$ N/A
Dr. Ernst-Ludwig Winnacker Co-Founder & Chairman Scientific Advisory Board N/A 1941(79 years old)
Dr. Gary Anthony Waanders Ph.D. VP of Investor Relations N/A N/A
Dr. René Goedkoop Acting Chief Medical Officer N/A N/A



Financial & Stock
Company's stock symbol is 0QGJ.L. Lastest price : 3.9020. Total volume :1.32k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.medigene.com

  • Host name: vs10315.internet1.de
  • IP address: 185.64.113.77
  • Location: Germany
  • Latitude: 51.2993
  • Longitude: 9.491
  • Timezone: Europe/Berlin

Loading ...
Loading ...


More informations about "Medigene Ag" on Search Engine

Medigene - Home

Medigene.com Medigene uses its proprietary platform technologies to modify T cells for the fight against tumor cells, thereby activating the body’s own immune defense mechanisms. Our focus is on the development of tumor-specific T cells (TCR-Ts).

Medigene - Home

Medigene.com Investors & Media. Welcome to the Investor Relations and Public Relations division of …

Medigene - Home

Medigene.com Axel Sven Malkomes has been appointed CFO and CBO of Medigene AG in April 2019 and …

Medigene - Home

Medigene.com Medigene is developing Living Immunotherapies, with the goal of providing …

Medigene - Home

Medigene.com AACR data show characteristics of Medigene's lead TCR candidate against solid tumors. …

Medigene - Home

Medigene.com Medigene develops three complementary immunotherapies to mobilize the powerful …

Medigene - Home

Medigene.com Reports & Presentations - Medigene - Home

Medigene - Home

Medigene.com Medigene’s DCs display a surface profile composed of high levels of molecules …

Medigene - Home

Medigene.com Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a …

Medigene - Home

Medigene.com Medigene is developing a pipeline of TCRs that could potentially be used in future TCR-Ts …

Medigene - Home

Medigene.com Please enter your e-mail address to register for Medigene’s newsletter (press release …

Medigene - Investors & Media - Detail

Medigene.com Mar 25, 2021 · Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer.

Medigene AG | LinkedIn

Linkedin.com Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The …

MediGene - Wikipedia

En.wikipedia.org Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. With its scientific expertise, Medigene is working on the development of innovative immunotherapies to treat cancer such as T cell receptor-modified T cells (TCR-Ts) or dendritic cell (DC) vaccines in fields of high medical need. The first product candidates are in clinical development and the Company has diverse preclinical programs. Medigene’s …

MEDIGENE AG (MDGEF) Stock Price, News, Quote & History

Finance.yahoo.com Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, has received approval from the Dutch regulatory authority...

Medigene AG: Further encouraging results from long-term

Pharmiweb.com Feb 09, 2021 · Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer.

MEDIGENE AG 0QGJ Market Stock | London Stock Exchange

Londonstockexchange.com MEDIGENE AG 0QGJ Overview - Search stock, chart, recent trades, company information, trading information, company news, fundamentals

MEDIGENE AG : MDG1 Stock Price | DE000A1X3W00 | …

Marketscreener.com Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies.

Medigene - Technologies - Immunotherapy Pipeline

Medigene.com Medigene is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The company concentrates on the development of personalized T cell-based immunotherapies.

MEDIGENE AG : MDG1 Stock Quotes and Prices | DE000A1X3W00

Marketscreener.com MEDIGENE AG : Delayed Quote, intraday chart, variations, volumes, technical indicators and last transactions, share MEDIGENE AG | Xetra: MDG1 | Xetra

Medigene - Investors & Media - Detail

Medigene.com Apr 10, 2021 · About Medigene Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based ...

Medigene : provides results for fiscal year 2020 and

Marketscreener.com Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer.

MEDIGENE AG (MDGEF) Company Profile & Facts - Yahoo Finance

Finance.yahoo.com Medigene AG, a biotechnology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company is developing personalized T cell-based therapies, with a focus ...

MDG1 | MediGene AG Stock Price & News - WSJ

Wsj.com View the latest MediGene AG (MDG1) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Medigene AG reports FY results (OTCMKTS:MDGEF) | Seeking Alpha

Seekingalpha.com Mar 25, 2021 · Medigene AG reports FY 2020 results Mar. 25, 2021 5:54 AM ET Medigene AG (MDGEF) By: Jignesh Mehta , SA News Editor Medigene AG ( OTCPK:MDGEF ) : FY GAAP EPS of …

Medigene AG - Company Profile - BCIQ

Bciq.biocentury.com For the biopharma industry investment, business development and competitive intelligence professionals who require information to support financing, partnering and licensing activities, BCIQ provides accurate information and context to support profitable and strategic decision making. Unlike other intelligence solutions, BCIQ exclusively supports the unique needs of the biopharma industry and ...

MDG1:Xetra Stock Quote - Medigene AG - Bloomberg Markets

Bloomberg.com Medigene AG operates as a biopharmaceutical company. The Company provides research, development, and commercialization of drugs for the treatment of cancer and autoimmune diseases.

MDG Stock Quote - Medigene AG - Bloomberg Markets

Bloomberg.com Medigene AG operates as a biopharmaceutical company. The Company provides research, development, and commercialization of drugs for the treatment of cancer and autoimmune diseases.

Medigene AG (MDG1) Quote - XETR | Morningstar

Morningstar.com Medigene AG is a Germany based biotechnology company. Along with its subsidiaries, the company is primarily engaged in developing immunotherapies to target various forms and stages of cancer with ...

Medigene AG: US patent office prolongs term of Medigene's

Finance.yahoo.com Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on …

Medigene AG: Medigene sells remaining rights and

Biospace.com Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies ...

Medigene : AACR data show characteristics of Medigene's

Marketscreener.com Apr 10, 2021 · Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer.

MEDIGENE AG NA O.N. (MDG1.DE) Stock Price, News, Quote

Finance.yahoo.com Find the latest MEDIGENE AG NA O.N. (MDG1.DE) stock quote, history, news and other vital information to help you with your stock trading and investing.

MDGEF | MediGene AG Company Profile & Executives - WSJ

Wsj.com MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of ...

MEDIGENE AG NA O.N. (MDG1.F) Stock Price, News, Quote

Finance.yahoo.com Find the latest MEDIGENE AG NA O.N. (MDG1.F) stock quote, history, news and other vital information to help you with your stock trading and investing.

MEDIGENE AG NA O.N. (MDG1.DE) Company Profile & Facts

Finance.yahoo.com Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in …

Medigene AG, MDG1X:GER summary - FT.com

Markets.ft.com Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the developm ent of personalized T cell-based immunotherapies.

MEDIGENE AG NA O.N. (MDG1.F) Company Profile & Facts

Finance.yahoo.com Medigene AG, a clinical stage immuno-oncology company, focuses on the development of T cell immunotherapies for the treatment of cancer. The company operates in …

Medigene : Change in the Executive Management Board

Marketscreener.com Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer.

MDGEF: Medigene AG - Stock Price, Quote and News - CNBC

Cnbc.com Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development.

Medigene AG: Addressing The CAR-T Market Pain Points

Seekingalpha.com Mar 18, 2015 · Based on the above analysis, I believe Medigene AG is a significantly undervalued company with an attractive adoptive immunotherapy platform. Share price appreciation could be catalyzed by clinical...

MEDIGENE AG : Shareholders Board Members Managers and

Marketscreener.com Medigene AG is a Germany-based biotechnology company that develops treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. The Company focuses on the development of personalized T cell-based immunotherapies. It develops three platforms: T-cell receptor (TCR)-modified T cells for ...

Medigene : Participation at upcoming virtual conferences

Marketscreener.com Apr 07, 2021 · Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer.

MDG1 Stock Price | MediGene AG Stock Quote (Germany: Xetra)

Marketwatch.com MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of ...

Medigene AG | LinkedIn

Dk.linkedin.com Medigene AG | 3.844 følgere på LinkedIn. We are empowering T cells to effectively fight cancer | Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on …

Medigene pulls plug on MDG1021 development program

Seekingalpha.com Jan 28, 2021 · Clinical stage immuno-oncology company Medigene AG (OTCPK:MDGEF) announces the discontinuation of its blood cancer treatment MDG1021's development program, as it looks to focus on the development ...

bluebird bio and Medigene Establish Strategic T Cell

Investor.bluebirdbio.com Sep 29, 2016 · Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development.

IRW-News: Medigene AG: Medigene AG: AACR-Daten zeigen

Finanzen.net Apr 10, 2021 · Planegg/Martinsried (pta003/10.04.2021/14:30) - Die Medigene AG (Medigene, FWB: MDG1, Prime Standard), ein Immunonkologie-Unternehmen mit klinischen Projekten fokussiert auf die Entwicklung T-Zell ...

MDGEF Stock Price | MediGene AG Stock Quote (U.S.: OTC)

Marketwatch.com MediGene AG is a biotechnology company, which engages in developing innovative, complementary treatment platforms that target various types and stages of cancer. It focuses on the development of ...

Medigene AG: Medigene announces dosing of first patient in

Biospace.com Feb 26, 2019 · Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies ...

Medigene AG in potential €1bn licence and R&D deal

European-biotechnology.com Furthermore, Cytovant and Medigene agreed to collaborate on research and discovery of two additional TCRs tailored for patients in East Asia. The deal triggered a US$10m upfront payment. Furthermore, MediGene is eglible to receive up to US$1bn in milestone payments and low low double-digit royalties if a programme hits the market in Greater ...

Medigene AG: Medigene appoints Axel-Sven Malkomes as CFO

Biospace.com Feb 11, 2019 · Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies ...

Kerstin Pino Tossi – Director Business Development

De.linkedin.com Director Business Development bei Medigene AG Planegg, Bayern, Deutschland 286 Kontakte. Zum Vernetzen anmelden Medigene AG. Ludwig-Maximilians Universität München. Dieses Profil melden Info Holding a degree in Molecular biology. More than eight years of experience in international biotechnology environment as scientist and project leader ...

Medigene : Identification of ten novel tumor-specific

Marketscreener.com Apr 10, 2021 · Medigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer.

Medigene AG (MDGEF) CEO Dolores Schendel on Q2 2019

Seekingalpha.com Aug 10, 2019 · Medigene AG (OTCPK:MDGEF) Q2 2019 Results Earnings Conference Call August 7, 2019 9:00 AM ET. Company Participants . Julia Hofmann - Head of Public and Investor Relations. Dolores Schendel - Chief ...